Guidelines

Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD Practice Guidelines, Third Edition.Toronto: CADDRA, 2011

National Health and Medical Research Council. Clinical Practice Points on the diagnosis, assessment and management of Attention Deficit Hyperactivity Disorder in children and adolescents. Commonwealth of Australia, 2012

National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults. NICE clinical guideline 72. Manchester: NICE, 2013

Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011;128:1007

Scottish Intercollegiate Guidelines Network. Management of Attention Deficit and Hyperkinetic Disorders in Children and Young People: A National Clinical Guideline. Edinburgh: SIGN, 2009

References

Castells X, Ramos-Quiroga JA, Bosch R, Nogueira M, Casas M. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews 2011, Issue 6

Clinical Excellence Commission. Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales - 2007 Final Report of the Special Review. Sydney: CEC, 2007

Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG,  Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA. ADHD drugs and serious cardiovascular events in children and young adults. New England Journal of Medicine 2011;365:1896-1904

Eysbouts Y, Poulton A, Salmelainen P. Stimulant medication in pre-school children in New South Wales. Journal of Paediatrics and Child Health 2011;47:870-4

Fayyad, De Graaf R, Kessler R, Alonso J, Andermeyer M et al, Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. The British Journal of Psychiatry 2007;190:402-409

Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. Journal of the American Medical Association 2011;306(24):2673-83

Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. Journal of the American Academy of Child and Adolescent Psychiatry 2011;50(10):978-90

Mazza M, D'Ascenzo F, Davico C, Biondi-Zoccai G, Frati G, Romagnoli E, Bassi B, Janiri L, Moretti C, Gaita F. Drugs for attention deficit-hyperactivity disorder do not increase the mid-term risk of sudden death in children: A meta-analysis of observational studies. International Journal of Cardiology 2013; May 13

Mick E, McManus DD, Goldberg RJ. Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. European Neuropsychopharmacology 2013;23(6):534-41

Mitchell PB, Levy F, Hadzi-Pavlovic D, Concannon PE, Hutchins P, Mulcahy DL, Clarke SD, Salmelainen PA, Warner A, Hughes CF. Practitioner characteristics and the treatment of children and adolescents with attention deficit hyperactivity disorder. Journal of Paediatrics and Child Health 2012;48:483-489

Polanczyk G, de Lima S, Horta BL, Biederman J, Rodhe LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. The American Journal of Psychiatry 2007;164:942-948

Poulton A J. Growth on stimulant medication; clarifying the confusion: a review. Archives of Disease in Childhood 2005; 90: 801-806

Salmelainen P. Trends in the prescribing of stimulant medication for the treatment of Attention Deficit Hyperactivity Disorder in children and adolescents in NSW. Sydney: NSW Department of Health, 2002

Salmelainen P. Trends in the prescribing of stimulant medication for the treatment of Attention Deficit Hyperactivity Disorder in adults in NSW. NSW Public Health Bulletin 2004;15(S-3)

Skounti M, Philalithis A, Galanakis E. Variations in prevalence of attention deficit hyperactivity disorder worldwide. European Journal of Pediatrics 2007;166:117-123

The Royal Australasian College of Physicians. Draft Australian Guidelines on Attention Deficit Hyperactivity Disorder (ADHD). St Kilda: RACP, 2009

Vitiello B, Elliott GR, Swanson JM, Arnold E, Hechtman L, Abikoff H, Molina BSG, Wells K, Wigal T, Jensen PS, Greenhill LL, Kaltman JR, Severe JB, Odbert C, Hur K, Gibbons R. Blood pressure and heart rate in the multimodal treatment of attention deficit/hyperactivity disorder study over 10 years. American Journal of Psychiatry 2012;69:167-177

Disclaimer: The NSW Ministry of Health is not responsible for the content or references of web sites that are external to the Ministry.  Listing of a reference does not necessarily constitute an endorsement by NSW Ministry of Health of the author(s) or all of the information presented in the reference. Linking to a web site does not necessarily constitute an endorsement by NSW Ministry of Health of the sponsor(s) of the web site or all of the information presented on the site.​​

Page Updated: Tuesday 26 March 2019
Contact page owner: Pharmaceutical Services